Divi's Laboratories, a Rs.2,500 crore pharma company from Hyderabad, has received minor setback during the quarter ended June 2014 and its net profit declined by 3.9 per cent to Rs.167.93 crore from Rs.174.71 crore due to lower other income resulted from lower forex gains. Its net sales increased by 24 per cent to Rs.639.76 crore from Rs.515.88 crore. Its other income declined by 76 per cent to Rs.12.69 crore from Rs.53.42 crore as its forex gains amounted to Rs.1.35 crore as compared to Rs.42.53 crore in the similar period of last year. With fall in profit its EPS declined slightly to Rs.12.65 from Rs.13.16 in the last period.
Divi has triple Certifications ISO-9001 (Quality Systems), ISO-14001 (Environment Management Systems) and OHSAS-18001 (Occupational Health and Safety Systems) for its manufacturing facilities and adheres to cGMP and standard operating practices in its manufacturing/operating activities and these certifications are renewed from time to time. The company has also obtained Food Safety System Certification 22000:2010 for vitamins and carotenoids. All the manufacturing sites have been inspected by US FDA.
Divi has a total of 38 drug master files (DMFs) with US FDA and 214 EDMFs and 18 CoS (Certificates of Suitability) with various European Union authorities as at the end of March 2014. Divi has filed a total of 8 patents for generic products.
Its product portfolio comprises of two broad segments viz., generic APIs (active pharma ingredients) and nutraceuticals and custom synthesis of APIs, intermediates and specialty ingredients for innovator pharma giants. The company operates predominantly in export markets and has a broad product portfolio under generics and custom synthesis. It's exports sales contributed 91 per cent to its total sales during March 2014. Business has been growing decently across both these segments and is broadly equal distributed.